SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Barkmanova, Jaroslava [1 ]
Petruzelka, Lubos [1 ,2 ]
Sedlackova, Eva [1 ,2 ]
Vocka, Michal [1 ,2 ]
Hejduk, Karel [3 ]
Bortlicek, Zbynek [3 ]
机构：
[1] Fac Med 1, Dept Oncol, Prague 2, Czech Republic
[2] Gen Fac Hosp Prague, Prague 2, Czech Republic
[3] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu165.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 0244
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
    Bai, Long
    Wang, Feng
    Li, Zhe-zhen
    Ren, Chao
    Zhang, Dong-sheng
    Zhao, Qi
    Lu, Yun-xin
    Wang, De-shen
    Ju, Huai-qiang
    Qiu, Miao-zhen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Xu, Rui-hua
    MEDICINE, 2016, 95 (51) : e4531
  • [2] Bevacizumab with chemotherapy for the first-line treatment of metastatic colorectal cancer: "NCI Slovakia" results
    Dolinsky, J.
    Salek, T.
    Hlavata, Z.
    Ivancova, H.
    Risnyovszka, Z.
    Mardiak, J.
    Koza, I
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [3] First-line bevacizumab (REV) and chemotherapy (CT) for metastatic colorectal cancer (mCRC); Results from a developing nation
    Franke, F. A.
    Azevedo, S. J.
    Gampel, O.
    Guimaraes, J. Q.
    Schaum, M. R.
    Murad, A.
    Coutinho, A. K.
    Oliveira, J. A.
    Matos Neto, J. N.
    Franca, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [5] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [6] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
    Shaotang Li
    Pan Dr Chi
    BioDrugs, 2011, 25 : 43 - 50
  • [7] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [8] Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
    Kozloff, M.
    Cohn, A.
    Christiansen, N.
    Flynn, P.
    Kabbinavar, F.
    Robles, R.
    Ulcickas-Yood, M.
    Sarkar, S.
    Hambleton, J.
    Grothey, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
  • [9] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [10] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
12345